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Abstract Type I DNA topoisomerases homologous to Esche- 
richia coli topoisomerase I normally only remove negative 
supercoils from DNA. Topoisomerases I from various eukaryotes 
share sequence homology and remove both positive and negative 
supercoils from DNA. Here we report that vaccinia virus 
topoisomerase I has significant difference in substrate preference 
from the other homologous type I topoisomerases. Vaccinia virus 
topoisomerase I shows a definite preference for removal of 
positive supercoiis. In contrast, topoisomerase I from human, 
wheat germ and Saccharomyces cerevisiae has little preference 
between positive and negative supercoils. The vaccinia enzyme 
may have evolved for functions required for optimal viral growth. 
Key words: Type I topoisomerases; Vaccinia virus; Positive 
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1. Introduction 
DNA topoisomerases regulate DNA topology by coupling 
DNA strand passage with the concerted breaking and rejoin- 
ing of DNA [1,2]. Type I DNA topoisomerases break and 
rejoin a single strand of DNA during catalysis. In E. coli, 
DNA topoisomerase I is responsible for the removal of excess 
negative superhelical tension from chromosomal DNA [3]. It 
normally only removes negative supercoils from DNA, a 
property also shared by other type I topoisomerases with 
which it shares sequence homology [4-9]. Topoisomerases I 
from various eukaryotic sources form another subfamily of 
type I topoisomerases [10-18] and relax both positive and 
negative supercoils. The loss of topoisomerase I function in 
E. coli due to a mutation in topA can be compensated by the 
expression of plasmid encoded topoisomerase I from S. cere- 
visiae [19] or human [20]. Although vaccinia virus topoisomer- 
ase I can also relax both positively and negatively supercoiled 
DNA in vitro like the human and S. cerevisiae topoisomerase 
I, its expression in E. coli cannot compensate for the loss of 
topA function [21]. This suggested that vaccinia topoisomerase 
I enzymes have significant differences in enzymatic properties 
when compared to these other eukaryotic enzymes, influenc- 
ing in vivo function. We have also reported previously [21] 
that the decline in E. coli viability due to the overexpression f 
vaccinia virus topoisomerase I could be suppressed by the 
presence of gyrase mutations or inhibitors. Our hypothesis 
to be tested here is that when expressed in E. coli, the vaccinia 
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virus topoisomerase I behaves more like the E. coli gyrase 
rather than the E. coli topoisomerase I in the relaxation of 
supercoiled DNA. 
According to the twin-supercoiled domain model [22], 
translocation of RNA polymerase during transcription elon- 
gation results in positive supercoils ahead of the RNA poly- 
merase complex and negative supercoils behind the complex. 
In E. coli, topoisomerase I can remove the negative supercoils 
while gyrase is responsible for the removal of the positive 
supercoils [3]. This model has been supported by the isolation 
of positively supercoiled pBR322 DNA topoisomers from E. 
coli cells treated with gyrase inhibitors [23] and the previous 
observation [24] that in vitro transcription i the presence of 
E. coli DNA topoisomerase I led to the accumulation of po- 
sitive supercoils in plasmid DNA substrate. In vitro transcrip- 
tion with T3 RNA polymerase and a plasmid DNA substrate 
with a T3 promoter was used here to examine the effect of 
different eukaryotic topoisomerases I on the superhelical state 
of DNA during transcription. The effect of vaccinia virus 
topoisomerase I xpression on accumulation f positive super- 
coils in E. coli was also examined to test the proposed hypoth- 
esis. 
2. Materials and methods 
2.1. Enzymes 
E. coli and vaccinia virus DNA topoisomerase I were purified from 
expression clones as described previously [25,26]. S. cerevisiae topo- 
isomerase I was a generous gift from Dr. J.C. Wang (Harvard Uni- 
versity). Wheat germ topoisomerase I was purchased from Promega 
and human topoisomerase I was obtained from TopoGEN. 
2.2. In vitro transcription reactions 
Plasmid pC15 [27] was relaxed completely with wheat germ topo- 
isomerase I and purified by phenol extraction and ethanol precipita- 
tion prior to use as substrate in the in vitro transcription reactions. 
The transcription reaction with T3 RNA polymerase were carried out 
under conditions as described previously [27]. DNA topoisomerase I 
from various sources was added to the reaction as indicated. The 
plasmid DNA was then analyzed by 2D agarose gel electrophoresis 
and visualized by hybridization to asp-labeled, MstlI digested pC15 
DNA [27]. Autoradiography was carried out using Kodak BIOMAX 
film. 
2.3. In vivo effect of vaccinia virus topoisomerase I expression on the 
accumulation of positive DNA supercoils 
E. coli MVll90 cells containing either plasmid p1940 expressing 
vaccinia topoisomerase I [21,26] or its derivative p1940A (with frame 
shift mutation in the vaccinia virus topoisomerase g ne) [21] were 
grown with 75 ktg/ml of novobiocin for 7 h at 30°C. The growth 
temperature was then shifted to 42°C to further increase the expres- 
sion of vaccinia virus topoisomerase I from p1940 [21]. After 7 h of 
further incubation, the cells were pelleted for plasmid DNA prepara- 
tion by the Wizard system (Promega). Two-dimensional gel electro- 
phoresis and in situ hybridization with a2P-labeled, PstI digested 
p1940 DNA were carried out as described previously [27]. 
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Fig. 1. Two-dimensional gel electrophoresis showing the effect of various type I DNA topoisomerases on transcription-driven supercoiling of 
DNA template. (A) Control, T3 RNA polymerase in vitro transcription with no topoisomerase added. (B) 1 U E. coli DNA topoisomerase 
I. (C) 2 U vaccinia virus DNA topoisomerase I. (D) 1 U S. cerevisiae DNA topoisomerase I. (E) 1 U wheat germ DNA topoisomerase I. 
(F) 1 U human DNA topoisomerase I. N, nicked DNA; R, relaxed DNA; +, positively supercoiled topoisomers; - ,  negatively supercoiled 
topoisomers. 
M. Fernandez-Beros, Y. Tse-Dinh/FEBS Letters 384 (1996) 265-268 267 
3. Results 
3.1. Vaccinia virus DNA topoisomerase I preferentially 
removes the positive supercoils generated uring 
transcription 
Both positive and negative supercoils were generated on the 
plasmid pC15 template from the transcription action of T3 
RNA polymerase. E. coli DNA topoisomerase I can only 
remove the negative supercoils. The expected accumulation 
of positive supercoils from the action of the E. coli DNA 
topoisomerase I was observed when the plasmid DNA was 
analyzed by 2-D agarose gel electrophoresis (Fig. 1B). In 
the presence of vaccinia virus DNA topoisomerase I, accumu- 
lation of negative supercoils was observed instead (Fig. 1C). 
The topoisomerase I from human, wheat germ and S. cerevi- 
siae gave similar results (Fig. 1D-F), with the DNA posses- 
sing a small number of positive superhelical turns, not signifi- 
cantly different from the control transcription reaction (Fig. 
1A) where no topoisomerase was present. This demonstrated 
that vaccinia virus topoisomerase I acted preferentially on the 
positive supercoils generated uring in vitro transcription 
while the other eukaryotic type I topoisomerases tested did 
not show any significant preference between the positive and 
negative supercoils. 
3.2. The action of  vaccinia virus DNA topoisomerase I on 
positive supercoils in vivo 
Treatment of E. coli cells with the gyrase inhibitor novo- 
biocin is known to lead to the presence of highly positively 
supercoiled plasmid DNA topoisomers [23]. Plasmid p1940 
expressing vaccinia virus DNA topoisomerase I and plasmid 
p1940A with a frame shift mutation in the enzyme coding 
region were prepared from E. coli MVll90 cells treated 
with novobiocin and analyzed by 2-D agarose gel electrophor- 
esis. Positively supercoiled p1940A could be readily observed 
(Fig. 2A) while the p1940 preparation had few positive topo- 
isomers (Fig. 2B). This demonstrated that vaccinia virus 
topoisomerase I expressed from p1940 removed the positive 
supercoils efficiently in vivo. 
4. Discussion 
The difference in substrate preference between vaccinia 
virus DNA topoisomerase I and the other type I topoiso- 
merases characterized here can account for the inability of 
the vaccinia virus DNA topoisomerase I to replace the topA 
function in E. coli. The yeast and human enzymes could com- 
plement for the lack of topA function probably because they 
showed no preference between the negative and positive 
supercoils. It has been reported [28] that R-loop formation 
is a major problem in the absence of E. coli DNA topoiso- 
merase I. Phenotypes associated with deficiency in the major 
RNAse H (rnhA) activity, as in the case of overexpression f
vaccinia virus topoisomerase I [21], can also be corrected by a 
defect in DNA gyrase [28]. By removing positive supercoils 
preferentially in vivo, vaccinia virus DNA topoisomerase I 
would not be able to suppress R-loop formation efficiently 
and compensate for the loss of E. coli DNA topoisomerase I. 
The size of vaccinia virus DNA topoisomerase I is about 
one third of that of the eukaryotic topoisomerase I of non- 
viral origins. It also differed from the non-viral eukaryotic 
topoisomerase I in its DNA cleavage sequence selectivity 
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Fig. 2. Removal of positive supercoils in vivo by vaccinia virus 
DNA topoisomerase I expressed in E. coli. 2-D gel electrophoresis 
of (A) plasmid p1940A (with frame shift mutation in vaccinia virus 
DNA topoisomerase I gene) or (B) p1940 expressing vaccinia virus 
DNA topoisomerase I. The DNA molecules were isolated from 
E. coli cells treated with the gyrase inhibitor novobiocin to generate 
positively supercoiled topoisomers. Plasmid p1940 DNA was iso- 
lated in its dimeric form while p1940A DNA was mainly mono- 
meric as observed previously [21]. N, nicked DNA; L, linear DNA; 
R, relaxed DNA; +, positively supercoiled topoisomers; --, nega- 
tively supercoiled topoisomers. 
[29]. Nevertheless, regions of the enzyme believed to comprise 
the active site for DNA cleavage are highly conserved [30]. 
Our results showed that even though eukaryotic topoisomer- 
ases I can in general relax both positively and negatively 
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supercoiled DNA, their action on DNA may result in different 
superhelical states. A prokaryotic enzyme DNA topoisomer- 
ase V has been purified from the hyperthermophilic methano- 
gen Methanopyrus kandleri and found to be related to eukar- 
yotic topoisomerase I [31]. It relaxes both positively and 
negatively supercoiled DNA but prefers positively over nega- 
tively supercoiled substrates [32]. 
Vaccinia virus DNA topoisomerase I is essential for virus 
growth [33]. Its preference for relaxation of positive supercoils 
may be a requirement of its role(s) in the vaccinia life cycle. It 
may act as a swivel during DNA replication to remove the 
positive supercoils generated ahead of the replication fork. 
The dynamics of topoisomerase action on transcription-gen- 
erated supercoiling can influence the structure and function of 
local DNA domains [34,35]. The localized DNA supercoiling 
generated by vaccinia virus topoisomerase I may be part of its 
functional role in the vaccinia life cycle and may also account 
for its lethal effect on E. coli cell growth. 
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